Literature DB >> 11352835

Adrenomedullin gene delivery attenuates renal damage and cardiac hypertrophy in Goldblatt hypertensive rats.

C Wang1, E Dobrzynski, J Chao, L Chao.   

Abstract

Adrenomedullin (AM) is a potent vasodilator and natriuretic peptide that plays an important role in cardiovascular function. In this study, we employed a somatic gene delivery approach to explore its potential protective role in renovascular hypertension. A single tail vein injection of adenovirus harboring the human AM gene significantly blunted a blood pressure increase that lasted for more than 3 wk in two-kidney one-clip (2K1C) hypertensive rats. The expression of human AM mRNA was detected in the kidney, adrenal gland, heart, lung, and liver, and immunoreactive human AM was detected in the plasma and urine of 2K1C rats after human AM gene delivery. A maximal blood pressure difference of 28 mmHg was observed 10 days after AM gene delivery, compared with that in rats injected with the control virus carrying the LacZ gene. Human AM gene delivery significantly attenuated increases in the ratio of left ventricular weight to heart weight, cardiomyocyte diameter, and fibrosis in the heart, as well as glomerular sclerosis, tubular injuries, and protein casts in the kidney. The beneficial effects of AM gene delivery were accompanied by increased urinary cAMP levels, indicating activation of AM receptors. These findings provide new insights into the role of AM in renovascular hypertension and may have significance in therapeutic applications in cardiovascular diseases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11352835     DOI: 10.1152/ajprenal.2001.280.6.F964

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  5 in total

1.  Tissue kallikrein reverses insulin resistance and attenuates nephropathy in diabetic rats by activation of phosphatidylinositol 3-kinase/protein kinase B and adenosine 5'-monophosphate-activated protein kinase signaling pathways.

Authors:  Gang Yuan; Juanjuan Deng; Tao Wang; Chunxia Zhao; Xizheng Xu; Peihua Wang; James W Voltz; Matthew L Edin; Xiao Xiao; Lee Chao; Julie Chao; Xin A Zhang; Darryl C Zeldin; Dao Wen Wang
Journal:  Endocrinology       Date:  2007-02-01       Impact factor: 4.736

2.  Regulation of myofibroblast differentiation and bleomycin-induced pulmonary fibrosis by adrenomedullin.

Authors:  Jacob Kach; Nathan Sandbo; Nan Sethakorn; Jesse Williams; Eleanor B Reed; Jennifer La; Xinyong Tian; Susan D Brain; Kavitha Rajendran; Ramaswamy Krishnan; Anne I Sperling; Konstantin Birukov; Nickolai O Dulin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-04-12       Impact factor: 5.464

Review 3.  Nano-sized carriers in gene therapy for renal fibrosis in vivo.

Authors:  Haruhisa Miyazawa; Keiji Hirai; Susumu Ookawara; Kenichi Ishibashi; Yoshiyuki Morishita
Journal:  Nano Rev Exp       Date:  2017-06-13

Review 4.  Targeting Adrenomedullin in Oncology: A Feasible Strategy With Potential as Much More Than an Alternative Anti-Angiogenic Therapy.

Authors:  Ramiro Vázquez; Maria E Riveiro; Caroline Berenguer-Daizé; Anthony O'Kane; Julie Gormley; Olivier Touzelet; Keyvan Rezai; Mohamed Bekradda; L'Houcine Ouafik
Journal:  Front Oncol       Date:  2021-01-06       Impact factor: 6.244

5.  Cardiovascular Effects of Autologous Bone Marrow-Derived Mesenchymal Stromal Cell Therapy With Early Tacrolimus Withdrawal in Renal Transplant Recipients: An Analysis of the Randomized TRITON Study.

Authors:  Maria Chiara Meucci; Marlies E J Reinders; Koen E Groeneweg; Suzanne Bezstarosti; Nina Ajmone Marsan; Jeroen J Bax; Johan W De Fijter; Victoria Delgado
Journal:  J Am Heart Assoc       Date:  2021-12-16       Impact factor: 6.106

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.